ArticleDiscover oncology2026
Desmoglein 2 is associated with dihydroartemisinin resistance in HeLa cervical cancer cells: a potential link to the PI3K/AKT signaling pathway.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The primary challenges in the clinical treatment of cervical cancer include metastasis, recurrence, proliferation, and drug resistance. DSG2 is a transmembrane desmosomal cadherin, has been implicated in various cancers, but its specific role in cervical cancer remains unclear.Recently, Dihydroartemisinin (DHA) has emerged as a promising antitumor drug. In this study, we aimed to investigate the impact of DSG2 on cervical cancer cells treated with DHA. Cellular assays demonstrated that DHA effectively inhibited the proliferation, migration, and invasion of HeLa cells. Increasing concentrations of DHA prolonged its effects and reduced HeLa cell proliferation. RNA-seq analysis revealed that DHA induced differential gene expression involved in cell migration, protein digestion and absorption, cytokine receptor interaction, the PI3K/AKT signaling pathway, and the Rap1 signaling pathway. DHA downregulated the expression of PI3K and AKT, while upregulating P53, ATM, cleaved caspase-3, and H2AX expression. Overexpression of DSG2 in HeLa cells increased resistance to DHA inhibition, whereas knockdown of DSG2 enhanced the inhibitory effects of DHA. This study highlights that DSG2 modulates the cytotoxicity of DHA, which is potentially associated with the PI3K/AKT signaling pathway, suggesting DSG2 as a candidate biomarker and a potential target for further investigation in cervical cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.